Fecal microbiota transplant (FMT) appears safe in decolonizing multi-drug resistant organisms (MDRO) from intestinal reservoirs in affected patients, even those who are highly immunosuppressed.
Patients with IBD should not alter their treatment during the COVID-19 pandemic; however, starting a new treatment regimen should be avoided.
A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.
Patients with inflammatory bowel disease (IBD) who tested positive for SARS-CoV-2 had a good overall prognosis, despite IBD maintenance treatment.
The COVID-19 pandemic has caused physicians in the New York area to reevaluate how they care for patients with gastrointestinal (GI) diseases.
Bezlotoxumab, both alone and in combination with actoxumab, was effective in preventing recurrent Clostridioides difficile infection without increased risk for adverse events.
Dual therapy with vonoprazan and low-dose amoxicillin had similar efficacy to triple-drug treatment for the eradication of Helicobacter pylori.
